Infant of 22 months of age with no anomalies born from a HCV- and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy.
The product label of ribavirin states that it is contraindicated during pregnancy, so the risk in its administering during pregnancy is concerned. We show a case of an infant of 22 months of age with no anomalies born from an HCV- and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy. The infant is neither HIV- nor HCV-infected.
Labarga
Pablo
P
Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain. pablolabarga@gmail.com
Pinilla
Javier
J
Cachorro
Iban
I
Ruiz
Yolanda
Y
del Prado
Yolanda Ruiz
YR
D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use; D007223:Infant; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011261:Pregnancy Trimester, First; D011262:Pregnancy Trimester, Second; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D015215:Zidovudine / Q000627:therapeutic use
D044966:Anti-Retroviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D019259:Lamivudine; D011092:Polyethylene Glycols; D012254:Ribavirin; D015215:Zidovudine; D019469:Indinavir; C100416:peginterferon alfa-2a